logo
PepGen Announces Presentations at the 2025 Muscular Dystrophy Association Clinical & Scientific Conference

PepGen Announces Presentations at the 2025 Muscular Dystrophy Association Clinical & Scientific Conference

Yahoo10-03-2025

BOSTON, March 10, 2025--(BUSINESS WIRE)--PepGen Inc. (Nasdaq: PEPG), a clinical-stage biotechnology company advancing the next generation of oligonucleotide therapies with the goal of transforming the treatment of severe neuromuscular and neurological diseases, today announced that the Company will be presenting two oral presentations as well as five posters at the 2025 Muscular Dystrophy Association (MDA) Clinical & Scientific Conference, being held March 16-19, 2025 in Dallas, TX. The oral presentations feature data from the ongoing CONNECT1-EDO51 clinical trial in Duchenne muscular dystrophy (DMD) and from the ongoing FREEDOM-DM1 clinical trial in myotonic dystrophy type 1 (DM1), which the Company recently announced.
Oral Presentations
Title: CONNECT1-EDO51: A 12-Week Open-Label Phase 2 Study to Evaluate PGN-EDO51 Safety and Efficacy in People with Duchenne Amenable to Exon 51 SkippingSession: Clinical Trial UpdatesDate & Time: Wednesday, March 19th at 8:45-9:00 a.m. CTPresenter: Paul Streck, MD, MBA, Executive Vice President, R&D
Title: FREEDOM-DM1: A Phase 1, Placebo-Controlled Single Ascending Dose Study to Evaluate PGN-EDODM1 in People with Myotonic Dystrophy Type 1 (DM1)Session: Clinical Trial UpdatesDate & Time: Wednesday, March 19th at 12:45-1:00 p.m. CTPresenter: Jane Larkindale, DPhil, Vice President, Clinical Science
Poster Presentations
Posters will be displayed beginning at 6:00-8:00 p.m. CT on Sunday, March 16th through Tuesday, March 18th in the conference exhibit hall.
Title: Mechanistic Characterization of Enhanced Delivery Oligonucleotide (EDO) PlatformPoster Number: #P21Presenter: Jane Larkindale, DPhil, Vice President, Clinical Science
Title: Nonclinical Data for PGN-EDODM1 Demonstrated Mechanistic and Meaningful Activity for the Potential Treatment of DM1Poster Number: #P48Presenter: Ashling Holland, PhD, Director, Research & Preclinical Development
Title: Single- and Repeat-Dose Nonclinical Data for PGN-EDO51 Demonstrated Favorable Pharmacology and Safety Profiles for the Treatment of DMDPoster Number: #P49Presenter: Ashling Holland, PhD, Director, Research & Preclinical Development
Title: FREEDOM-DM1: A Phase 1, Placebo-Controlled Single Ascending Dose Study to Evaluate PGN-EDODM1 in People with Myotonic Dystrophy Type 1 (DM1)Poster Number: #O45Presenter: Jennifer Shoskes, PharmD, Associate Director, Clinical Development
Title: CONNECT1-EDO51: A 12-Week Open-Label Phase 2 Study to Evaluate PGN-EDO51 Safety and Efficacy in People with Duchenne Amenable to Exon 51 SkippingPoster Number: #O74Presenter: Bassem Morcos, MD, Medical Director, Clinical Development
Following the conference, the presentations presented at the MDA Clinical & Scientific Conference will be available on the Investors page of PepGen's website under Scientific Publications.
About PGN-EDODM1
PGN-EDODM1, PepGen's investigational candidate in development for the treatment of DM1, utilizes the Company's proprietary EDO technology to deliver a therapeutic oligonucleotide that is designed to restore the normal splicing function of MBNL1, a key RNA splicing protein. PGN-EDODM1 is designed to directly address the deleterious effects of cytosine-uracil-guanine (CUG) repeat expansion in the DMPK transcripts which sequester MBNL1, by binding to the pathogenic CUG trinucleotide repeat expansion present in the DMPK transcripts, disrupting the binding between the CUG repeat expansion and MBNL1. We believe this mechanism will allow the DMPK transcripts to continue performing its normal function within the cell, while also liberating MBNL1 to correct downstream mis-splicing events. We believe that this innovative therapeutic approach has considerable advantages over oligonucleotide modalities that rely on knockdown or degradation of the DMPK transcripts. The FDA has granted PGN-EDODM1 both Orphan Drug and Fast Track Designations for the treatment of patients with DM1.
About PGN-EDO51
PGN-EDO51, PepGen's investigational candidate in development for the treatment of DMD, utilizes the Company's proprietary EDO technology to deliver a therapeutic oligonucleotide that is designed to target the root cause of this devastating disease. PGN-EDO51 is designed to skip exon 51 of the dystrophin transcript, an established therapeutic target for approximately 13% of DMD patients, thereby aiming to restore the open reading frame and enabling the production of a truncated, yet functional dystrophin protein. The FDA has granted PGN-EDO51 both Orphan Drug and Rare Pediatric Disease Designations for the treatment of patients with DMD amenable to an exon-51 skipping approach.
About PepGen
PepGen is a clinical-stage biotechnology company advancing the next generation of oligonucleotide therapies with the goal of transforming the treatment of severe neuromuscular and neurological diseases. PepGen's EDO platform is founded on over a decade of research and development and leverages cell-penetrating peptides to improve the uptake and activity of conjugated oligonucleotide therapeutics. Using these EDO peptides, we are generating a pipeline of oligonucleotide therapeutic candidates designed to target the root cause of serious diseases.
For more information, please visit PepGen.com. Follow PepGen on LinkedIn and X.
View source version on businesswire.com: https://www.businesswire.com/news/home/20250310990282/en/
Contacts
Investor Dave Borah, CFASVP, Investor Relations and Corporate Communicationsdborah@pepgen.com
Media Julia DeutschLyra Strategic AdvisoryJdeutsch@lyraadvisory.com

Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

Top Analyst Cuts Tesla to 'Hold' as Robotaxi Optimism Faces Scrutiny
Top Analyst Cuts Tesla to 'Hold' as Robotaxi Optimism Faces Scrutiny

Yahoo

time18 minutes ago

  • Yahoo

Top Analyst Cuts Tesla to 'Hold' as Robotaxi Optimism Faces Scrutiny

June 10- Robert W. Baird analyst Ben Kallo downgraded Tesla (NASDAQ:TSLA) to a "Hold" rating from "Buy". Kallo maintained his price target of $320 per share. This marks the analyst's first downgrade for the electric vehicle maker in three years. Kallo cited concerns over "heightened expectations" surrounding Tesla's upcoming robotaxi launch event. He also highlighted potential "key-man risk" related to CEO Elon Musk's activities and associations. The analyst noted TSLA stock has surged over 20% since first-quarter results, likely reflecting existing optimism about the robotaxi and a more affordable vehicle. The analyst expressed skepticism about the projected speed of the robotaxi service rollout, describing it as potentially "a bit too optimistic." Tesla was recently listed by Austin, Texas, authorities as being in the "testing" phase for autonomous vehicles. Competitor Waymo is listed in the "deployment" phase in the same city. Kallo's decision also factored in increased competition, potential changes to vehicle delivery timelines, and the gradual reduction of electric vehicle tax credits. Despite the downgrade, Tesla shares rose about 3% in pre-market trading on Tuesday. This movement coincided with the apparent easing of tensions between Musk and former President Donald Trump, who recently confirmed continued use of Tesla products. This article first appeared on GuruFocus. Sign in to access your portfolio

Top Stock Movers Now: Walt Disney, JM Smucker, McDonald's, and More
Top Stock Movers Now: Walt Disney, JM Smucker, McDonald's, and More

Yahoo

time27 minutes ago

  • Yahoo

Top Stock Movers Now: Walt Disney, JM Smucker, McDonald's, and More

U.S. equities were mostly edging higher at midday with the market watching for developments in U.S.-China trade negotiations. Walt Disney paid $438.7 million to gain complete control of Hulu from Comcast. J.M. Smucker warned about the economic environment, and shares plunged.U.S. equities were mostly edging higher at midday as the market continued to wait for updates on U.S.-China trade talks. The S&P 500 and Nasdaq were up slightly, and the Dow Jones Industrial Average was near flat. Energy-related companies, including Halliburton (HAL), APA (APA), and Chevron (CVX), advanced along with the price of oil on optimism the trade talks will be successful. Shares of Walt Disney (DIS) climbed when the entertainment giant paid Comcast (CMCSA) $438.7 million to take full control of the Hulu streaming service. Comcast shares rose as well. Casey's General Stores (CASY) shares soared to a record high when the convenience store operator beat profit and sales estimates and boosted its dividend on strong in-store and fuel sales. J.M. Smucker (SJM) was the worst-performing stock in the S&P 500 after the jelly and snack food maker missed sales forecasts and gave weak guidance as it dealt with 'a dynamic and evolving external environment.' Shares of United Natural Foods (UNFI) continued their decline from yesterday following its announcement that a cyberattack disrupted operations. The food distributor said it was withholding updated earnings per share and sales guidance as it determines what impact the hack might have. McDonald's (MCD) shares dropped on a double downgrade from Redburn Atlantic, which pointed to falling foot traffic and the potential effect of soaring weight-loss drug demand on its sales. Gold futures fell. The yield on the 10-year Treasury note was little changed. The U.S. dollar gained on the pound and yen, and was little changed against the euro. Prices were up for most major cryptocurrencies. Read the original article on Investopedia Error while retrieving data Sign in to access your portfolio Error while retrieving data Error while retrieving data Error while retrieving data Error while retrieving data

Firms launch tools to help shippers measure tariff costs
Firms launch tools to help shippers measure tariff costs

Yahoo

time28 minutes ago

  • Yahoo

Firms launch tools to help shippers measure tariff costs

As shifting tariffs continue to impact global supply chains, Flexport and C.H. Robinson have introduced tools aimed at helping businesses navigate duties impacting international shipments. Flexport, a San Francisco-based global logistics technology company, recently launched the Flexport Tariff Simulator, a tool designed to help businesses estimate landed costs and navigate tariffs in real time. Third party logistics provider C.H. Robinson (Nasdaq: CHRW) has added the U.S. Tariff Impact Analysis tool to its global shipper platform to help businesses assess their overall duty exposure, while providing precise cost analysis of each shipment. Mike Short, president of global forwarding at C.H. Robinson said the tool assesses trade complexities more effectively. 'With this tool a national retailer could identify high-volume stock keeping units coming from one point of origin, then quickly compare total duty spend along various alternative sources — then reroute future supply where needed,' Short said in a news release. Ryan Petersen, Flexport founder and CEO, said their customers have been asking for more clarity on the impact of import tariffs on shipments. 'Our engineering team built the Flexport tariff simulator in response to meet that need in the face of all the uncertainty caused by rapid policy changes,' Petersen said in a news release. 'We want to help merchants avoid expensive surprises.' Flexport's tariff simulator includes an interactive map that allows users to see trade data around the world, including the total value of imports from a given country, the current average duty rate, and the percentage of total U.S. imports coming from that country. The tool is available to the general public at Along with the tariff simulator, Flexport is also launching a searchable catalog of harmonized tariff schedule codes to navigate classification requirements, special duty rates and customs clearance processes. Flexport and C.H. Robinson are not the only firms launching tools to help shippers, logistics professionals and consumers assess the impact of import tariffs. In March, UPS (NYSE: UPS) created an automatic tariff calculator for online shoppers — UPS Global Checkout. The parcel carrier's landed cost calculator allows e-commerce merchants to integrate it into their online stores so customers see the import duties, taxes and fees upfront at checkout. E-commerce platform provider Shopify (Nasdaq: SHOP) launched a tariff calculator in May that helps determine duties and taxes on international shipments. Agtools, a provider of software solutions for the food industry, debuted a tool in February that enables users to calculate import levies across all commodities in real time and create scenarios that will impact supply, merchandising and pricing. The post Firms launch tools to help shippers measure tariff costs appeared first on FreightWaves. Sign in to access your portfolio

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into the world of global news and events? Download our app today from your preferred app store and start exploring.
app-storeplay-store